Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Obesity (BMI > 30 kg/m2) was significantly more prevalent in the low Dtotal group (30% versus 13%, p = 0.01) as a result of weight being higher (median 79 kg versus 73 kg, p = 0.03) and 1,25(OH)2D was significantly lower (median 82 pmol/L versus 110 pmol/L, p < 0.001) No other baseline variables were significantly different between Dtotal groups. (See Table 1) One-hundred-and-forty-three of the 158 patients included at baseline had disease activity evaluated one year after diagnosis, and were eligible for evaluation of remission. (See Fig. 1).Baseline characteristic according to Dtotal status at diagnosis.Low Dtotal (<50 nmol/L) N = 67 (42%)Normal Dtotal (≥50 nmol/L) N = 91 (58%)Group comparison (p-value)Total N = 158Age at inclusion, YearsMedian 52IQR 44 to 63Median 53IQR 41 to 630.83Median 53IQR 43 to 63Female sexN = 42 (63%)N = 62 (68%)0.48N = 104 (66%)Symptom duration prior to diagnosis, monthsMedian 3.3IQR 2.4 to 4.8Median 3.2IQR 2.5 to 4.40.81Median 3.2IQR 2.5 to 4.6Ciclosporin (yes)N = 36 (54%)N = 42 (46%)0.35N = 78 (49%)ACPA-status positiveN = 39 (58%)N = 53 (58%)0.99N = 92 (58%)IgM-RF-status positiveN = 39 (58%)N = 63 (69%)0.15N = 102 (65%)NTJ (0 to 28)Median 10IQR 6 to 16Median 10IQR 5 to 150.25Median 10IQR 5 to 15NSJ (0 to 28)Median 9IQR 5 to 12Median 8IQR 5 to 120.67Median 8IQR 5 to 12VASpatient-global (0 to 100 mm)Median 50IQR 26 to 72Median 50IQR 29 to 720.61Median 50IQR 29 to 72VASpatient-pain (0 to 100 mm)Median 48IQR 27 to 72Median 46IQR 29 to 720.96Median 48IQR 29 to 70VASdoctor-global(0 to 100 mm)Median 58IQR 42 to 70Median 55IQR 36 to 680.41Median 58IQR 38 to 68ESR, mm/hourMedian 32IQR 9 to 48Median 23IQR 11 to 470.65Median 28IQR 10 to 47CRP, nmol/LMedian 24IQR 9 to 51Median 17.3IQR 9 to 390.19Median 20.2IQR 9 to 43DAS28-CRP (0 to 9)Median 5.3IQR 5.6 to 6.1Median 5.2IQR 4.4 to 5.90.32Median 5.3IQR 4.5 to 5.9HAQ (0 to 3)Median 1IQR 0.5 to 1.5Median 0.9IQR 0.4 to 1.50.88Median 0.7IQR 0.4 to 1.5Creatinine µmol/LMedian 75IQR 67 to 82Median 77IQR 68 to 830.53Median 76IQR 67 to 82BMI ≥ 30 (kg/m2)N = 20 (30%)N = 12 (13%)0.01N = 32 (20%)Weight, kgMedian 79IQR 64 to 92Median 73IQR 64 to 820.03Median 76IQR 64 to 85Height, cmMedian 170IQR 166 to 175Median 170IQR 164 to 1750.76Median 170IQR 165 to 1751,25(OH)2D, pmol/LMedian 82IQR 65 to 99Median 110IQR 80 to 139<0.001Median 95.5IQR 70 to 119Season of diagnosis (Winter)N = 44 (66%)N = 37 (41%)0.002N = 81 (51%)Abbreviations: Dtotal: The sum of 25OHD2 and 25OHD3.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
One-hundred-and-sixty patients were recruited from five Danish University Clinics from October 1999 to October 2002 in the CIMESTRA-study.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis
Study design awaiting verification · Scientific Reports · 2020
Original publication title
Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
The study evaluates associations between serum vitamin D metabolites at diagnosis and one-year remission, in early diagnosed rheumatoid arthritis(RA). The CIMESTRA-cohort comprised 160 newly diagnosed RA patients, treated aiming at remission. Vitamin D supplementation was recommended according to national guidelines. Dtotal(25OHD2 + 25OHD3) was dichotomized at 50 nmol/L, 1,25(OH)2D was categorized in tertiles. Primary outcome was remission(DAS28-CRP ≤ 2.6) after one year. Associations were evaluated using logistic regression, further adjusted for pre-specified potential confounders: Age, sex, symptom-duration before diagnosis, DAS28-CRP and season of diagnosis.
Results are presented as Odds Ratios(OR) with 95% Confidence Intervals(95%CIs). In univariate analyses, neither Dtotal nor 1,25(OH)2D were associated with remission. In adjusted analyses, low Dtotal was associated with higher odds for remission; OR 2.6, 95%CI (1.1; 5.9) p = 0.03, with season impacting results the most. One-year remission was lower in patients with diagnosis established at winter. In conclusion, low Dtotal at diagnosis was associated with increased probability of achieving one-year remission in early RA when adjusting for covariates.
Diagnosis in winter was associated with lower odds for one-year remission. Results suggest that season act as a contextual factor potentially confounding associations between vitamin D and RA disease-course. The finding of low Dtotal being associated with higher one-year remission remains speculative.
Authors’ abstract
The study evaluates associations between serum vitamin D metabolites at diagnosis and one-year remission, in early diagnosed rheumatoid arthritis(RA). The CIMESTRA-cohort comprised 160 newly diagnosed RA patients, treated aiming at remission. Vitamin D supplementation was recommended according to national guidelines. Dtotal(25OHD2 + 25OHD3) was dichotomized at 50 nmol/L, 1,25(OH)2D was categorized in tertiles. Primary outcome was remission(DAS28-CRP ≤ 2.6) after one year. Associations were evaluated using logistic regression, further adjusted for pre-specified potential confounders: Age, sex, symptom-duration before diagnosis, DAS28-CRP and season of diagnosis.
Results are presented as Odds Ratios(OR) with 95% Confidence Intervals(95%CIs). In univariate analyses, neither Dtotal nor 1,25(OH)2D were associated with remission. In adjusted analyses, low Dtotal was associated with higher odds for remission; OR 2.6, 95%CI (1.1; 5.9) p = 0.03, with season impacting results the most. One-year remission was lower in patients with diagnosis established at winter. In conclusion, low Dtotal at diagnosis was associated with increased probability of achieving one-year remission in early RA when adjusting for covariates.
Diagnosis in winter was associated with lower odds for one-year remission. Results suggest that season act as a contextual factor potentially confounding associations between vitamin D and RA disease-course. The finding of low Dtotal being associated with higher one-year remission remains speculative.
Publication and source details
Original title: Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis
M. Herly; K. Stengaard-Pedersen; P. Vestergaard; R. Christensen; S. Möller; M. Østergaard; P. Junker; M. L. Hetland; K. Hørslev-Petersen; T. Ellingsen
Scientific Reports · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T17:34:00.291692+00:00
DOI: 10.1038/s41598-020-64284-x · PMC7192905